Triple-drug attack aims to stop melanoma from coming back
Disease control
Ongoing
This Phase 2 trial tests whether giving a mix of targeted drugs and immunotherapy before and after surgery can reduce the risk of melanoma returning in people with high-risk, resectable tumors. About 95 participants will receive vemurafenib, cobimetinib, and atezolizumab in diffe…
Phase: PHASE2 • Sponsor: Fondazione Melanoma Onlus • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC